About Diabetes
Complications
Warning Signs
Screening Test
Donate Now
E-Lerts™
Index
Latest News
Diabetes Terms
Health & Fitness
Online Press Center
New Drug Liraglutide Is Promising in Type 2 Diabetes
Treatment
posted 06/16/04
Liraglutide a long-acting glucagons-like peptide 1 improved
glycemic control in Type 2 diabetes without weight gain.
In a study of type 2 diabetic patients, treatment with liraglutide (NN2211), an investigational long-acting glucagon-like peptide 1 derivative administered by injection once daily, improved glycemic control without increasing weight, European investigators report in the June issue of Diabetes Care.
Commenting on his team's findings, Dr. Sten Madsbad from
Hvidovre Hospital in Denmark tstated that "insulin and sulfonylurea treatment
also improve glycemic control, but increase weight. The present trial is the
first to demonstrate long term improvement in glycemic control with a
concomitant weight loss in type 2 diabetic patients."
Dr. Madsbad and colleagues conducted a double-blind, parallel-group,
placebo-controlled trial with an open-label comparator arm. Involved were 193
type 2 diabetics with a mean HbA1c of 7.6%. The researchers randomly assigned
subjects to one of five fixed-dosage groups of liraglutide (0.045, 0.225, 0.45,
0.60, or 0.75 mg), placebo, or open-label sulfonylurea (glimepiride, 1-4 mg).
In intention-to-treat analysis based on 190 patients, HbA1c fell in all but the
lowest liraglutide dosage group, the team reports. In the 0.75-mg liraglutide
group, HbA1c fell by a significant 0.75 percentage points and fasting glucose by
1.8 mmol/L compared with placebo.
Improvement in glycemic control was observed after one week and maintained
throughout the 12-week trial. After 12 weeks 59% of patients in the two highest
liraglutide dosage arms achieved HbA1c of 7% or less.
Liraglutide 0.75-mg provided HbA1c and fasting serum glucose control comparable
to the sulfonylurea comparator glimepiride, and there were "fewer hypoglycemic
events in the liraglutide arm," Dr. Madsbad added.
Moreover, patients taking liraglutide did not gain weight. In fact, subjects in
the 0.45 mg liraglutide arm experienced a statistically significant 1.2 kg
decrease in body weight compared with placebo. Body weight increased "slightly"
in the glimepiride arm.
Thus the researchers conclude that the agent "shows considerable promise as a
once-daily therapy in type 2 diabetes."
Source: Diabetes In Control.com: Diabetes Care 2004;27:1335-1342. PowerPoint Presentation Available.
|
|
|
To be sure and come back to keep up with all the
Latest News and important information for diabetics - and to remind
yourself to manage and control your diabetes, click the yellow link
below
to add a small icon of our Defeat Diabetes® "Torch"
logo to your desktop. All you need to do after that is
click on the "Torch" to open our website.
Remember, we're here for you!
Translate this page into Spanish using FreeTranslation.com. © Copyright 2001 - 2004, Defeat Diabetes Foundation, Inc., All Rights Reserved |
We
subscribe to the HONcode principles